Phase II Study of Irinotecan,Oxaliplatin Plus TS-1 in Untreated Metastatic Colorectal Cancer
Status:
Unknown status
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
Patients will be treated with irinotecan (150 mg/m2) followed by oxaliplatin (85 mg/m2) on
day 1 and S-1 (80 mg/m2/day) from day 1 to 14 every 3 weeks. Patients will receive up to a
planned treatment of maximum 12 cycles of chemotherapy. Response assessment will be performed
every 2 cycles of chemotherapy.